Cube Labs, the Italian venture builder in the life sciences sector listed on EGM Pro, and FTherapeutics, a Spanish cluster of companies that provides consulting services for the discovery and development of new drugs, announce a strategic collaboration agreement.
Through the agreement, FTherapeutics, together with its cluster companies Synthelia Organics, a provider of medicinal chemistry and synthesis solutions for the pharmaceutical and biotechnology industries, and Nostrum Biodiscovery, a company specializing in AI-based biotechnology solutions for drug discovery, will collaborate with Cube Labs to advance early-stage drug discovery and development projects.
FTherapeutics brings together professionals with long experience in multinational pharmaceutical companies such as Ely Lilly and GSK, experts in disciplines such as computational chemistry, organic chemistry, biochemistry and medicinal chemistry.
The collaboration will leverage the complementary strengths of both parties. Cube Labs will bring its expertise in identifying and building promising life science companies from the ground up. FTherapeutics and its cluster companies will contribute their expertise in drug discovery, personalized synthesis, route optimization , and artificial intelligence.
“We are thrilled to partner with FTherapeutics and the companies in the cluster,” said Filippo Surace, CEO and founder of Cube Labs This partnership will allow us to further enhance the value of our portfolio companies and accelerate the development of innovative new medicines.”
“This agreement represents an important step forward for FTherapeutics and for our companies in the cluster,” said Rafael Ferritto, Director of FTherapeutics. By partnering with Cube Labs, we will be able to bring our expertise to a wider range of early-stage drug discovery projects.” (Photo by Roberto Sorin on Unsplash)
ALL RIGHTS RESERVED ©